Merck Sharp + Dohme Corp.

Iomet Pharma Ltd.

Meredeth Ann McGowan

Yongxin Han

Abdelghani Achab

Xavier Fradera

Nunzio Sciammetta

Kun Liu

Hongjun Zhang

Jason David Katz

Catherine M White

Joey Lee Methot

Derun Li

Yongqi Deng

Wensheng Yu

Kin Chiu Fong

Neville J Anthony

David L Sloman

Jianmin Fu

Matthew Christopher

Shimin Xu

Changwei Mu

Chaomin Li

Lihu Yang

Michael D Altman

David James Witter

Jongwon Lim

Solomon D Kattar

Rong Zhang

Craig R Gibeau

Feng Shi

Qinglin Pu

Phillip Martin Cowley

Francesc Xavier Fradera Llinas

Alan Wise

Kathryn Ann Lipford

Brett A Hopkins

Xiaoli Zhao

Yudith Garcia

Thomas James Brown

Yabin Li

Xiansheng Leng

Sixing Zhang

Baijun Ye

Joseph A Kozlowski

Timothy J Guzi

Shuwen He

Liangqin Guo

Purakkattle J Biju

John W Lampe

Yuan Tian

Liping Yang

Indu T Bharathan

Ravi Kurukulasuriya

Ning Fu

Deqian Bian

Xiaona Wang

Guoquan Xu

Neville John Anthony

Thomas J Brown

Phillip M Cowley

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

The instant invention provides compounds of formulas Ia and Ib which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. 

Purine inhibitors of human phosphatidylinositol 3-kinase delta

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I) Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted phenyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted pyridinyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein are substituted imidazopyridine compounds of formula (I) which are inhibitors of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan-2,3-dioxygenase (TDO) enzymes: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. 

Substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof:  Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Compounds as indoleamine 2,3-dioxygenase inhibitors

Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the general formula (I) detailed within. 

Substituted bicyclic fused ring compounds as indoleamine-2,3-dioxygenase inhibitors

The instant invention provides compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. 

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. 

Growing community of inventors

Boston, MA, United States of America

Meredeth Ann McGowan